ALS drug trial halted before it even began
NCT ID NCT03508453
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study aimed to test an experimental drug called IC14 in 50 people with rapidly progressing ALS. Participants would have received either the drug or a placebo intravenously twice a week for 12 weeks. The goal was to measure changes in disease markers and track safety. However, the trial was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.